A Phase 3 Study of SME3110 (Fluvoxamine Maleate) in Pediatric/Adolescent Subjects With Obsessive Compulsive Disorder
Phase of Trial: Phase III
Latest Information Update: 06 Dec 2017
Price : $35 *
At a glance
- Drugs Fluvoxamine (Primary)
- Indications Obsessive-compulsive disorders
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors AbbVie
- 03 Aug 2016 Status changed from active, no longer recruiting to completed.
- 25 Jan 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Aug 2016, according to ClinicalTrials.gov record.
- 31 Aug 2015 Planned End Date changed from 1 Dec 2016 to 1 Aug 2016 as reported by ClinicalTrials.gov